A new weapon in the fight against osteoarthritis?
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating osteoarthritis. This is based on a polysaccharide, a long-chain sugar molecule, originating from brown algae. When chemically modified, this “alginate” reduces oxidative stress, has an anti-inflammatory effect in cell culture tests and suppresses the immune reaction against cartilage cells, thereby combating the causes of arthritis. The research is, however, still in its infancy.
Osteoarthritis is the most-widespread joint disease, with around 90 percent of all people over 65 being affected to varying degrees, but this degenerative disease is also widespread amongst younger people. In arthritis, the cartilage in the joint, a type of protective layer on bones that “lubricates” the joint, degenerates over time. This can be extremely painful for sufferers, because inflammatory reactions are associated with cartilage degeneration. In the later stages of the disease, bones are no longer adequately protected and can directly rub against each other.
Osteoarthritis can affect all joints in the body, but most often affects the knee joint, hip joint and fingers. The disease has been considered incurable until now. Current treatment methods, such as anti-inflammatory drugs and painkillers, mainly address the symptoms. Often, the only remaining option is an operation to replace the affected joint with an artificial one.
Initial research results are encouraging
In laboratory tests, the team led by ETH researcher Marcy Zenobi-Wong and Empa researcher Katharina Maniura has now succeeded, together with SINTEF in Norway, in identifying a substance with the potential to halt cartilage degeneration in joints. This substance is the polysaccharide alginate extracted from the stems of brown algae – or more precisely cuvie (Lat. Laminaria hyperborea), which is similar to specific extracellular biomolecules in cartilage. The researchers chemically modified the alginate with sulfate groups and then added it in dissolved form to cell cultures to examine the reaction of various cell types to the modified polysaccharide. This revealed that alginate sulfate can significantly reduce oxidative stress, which is a frequent cause of cell damage or even cell death, and the more sulfate groups attached to the alginate molecule, the greater this reduction.
Alginate sulfate was also able to suppress the inflammatory reaction, again depending on the number of sulfate groups, and was able to down-regulate the expression of genes that trigger an inflammatory reaction in both human cartilage cells, known as chondrocytes, and in macrophages, the “scavenger cells” of our immune system. The algal molecules should therefore slow down cartilage degeneration. “The hope is that they can even stop this degeneration,” says Empa researcher Markus Rottmar.
Further research work necessary
The alginate sulfates have so far only been tested in vitro, i.e. in the laboratory with cell cultures. However, the encouraging results mean that research will now continue. The next stage is to test the substances on animals. If this is also successful, clinical trials can then be conducted on people. These tests are, however, laborious and time-consuming. If everything were to work perfectly, it would still be a few years before arthritis patients could be treated with alginate sulfate.
Learn more: Treating arthritis with algae
The Latest on: Osteoarthritis
- What’s in Your Horse’s Joint Supplement? on February 18, 2019 at 9:57 am
Can you name one of the most common causes of lameness in horses? If you said osteoarthritis (OA), you’re right. As common as it is, OA remains an incurable disease, and once it presents itself ... […]
- Innovate UK awards AKLRD £675,000 for osteoarthritis drug on February 18, 2019 at 4:44 am
AKL Research and Development’s (AKLRD) early-stage osteoarthritis drug has won a prestigious award from Innovate UK, as a potential “game-changing” treatment. The drug APPA has been awarded £675,000 b... […]
- History Reveals Osteoarthritis May Be All About Activity on February 18, 2019 at 1:26 am
History reveals osteoarthritis may be all about activity. This condition is painful and can be debilitating. It is often linked with the aging process, but recent research found that it may be due ... […]
- UK-based Biotech Company, AKLRD, Rewarded for Unique Approach to Drug Development by UK Government's Innovation Body on February 17, 2019 at 4:01 pm
STEVENAGE, England, Feb. 17, 2019 /PRNewswire/ -- AKL Research and Development (AKLRD) today announces its investigational medicine for osteoarthritis (OA) has been awarded a prestigious grant from In... […]
- Bass great Bob Magnusson to be saluted at free Dizzy's concert on February 17, 2019 at 1:59 pm
In 2014, bass great Bob Magnusson was forced to cut back his live performances to just once a week because of his acute osteoarthritis. Now, no longer to meet his own exacting musical standards, he ha... […]
- Osteoarthritis Drugs Market Worth US$ 11,226.1 Mn by 2026 on February 17, 2019 at 1:41 am
Albany, NY -- (SBWIRE) -- 02/17/2019 -- Transparency Market Research (TMR) has published a new report titled, "Osteoarthritis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and ... […]
- OSU Wexner Medical Center First U.S. Site To Implant Device for Knee Osteoarthritis on February 16, 2019 at 10:08 pm
The Calypso Knee System, developed by Moximed, Inc., is designed to act as a shock absorber for the inner knee. A clinical trial is examining how the device may relieve pain and slow the progression o... […]
- New Knee Device Helping Patients With Intermediate Osteoarthritis on February 15, 2019 at 3:17 pm
PITTSBURGH (KDKA) — For firefighter Chuck Stenger, the past 20 years have been full of pain. He remembers when it first started. “Knelt down to start treating a patient, and it felt like a ... […]
- Glenohumeral Degenerative Disease: Osteoarthritis on February 14, 2019 at 7:34 am
Degenerative osteoarthritis (OA) of the glenohumeral joint may be a primary, idiopathic process. However, it can also be secondary to a number of inciting factors including post-traumatic, previous ca... […]
- Repeat Zilretta Administration Safe, Effective for Osteoarthritis Knee Pain, Says Study on February 13, 2019 at 9:22 am
Zilretta is indicated as an intra-articular injection. Repeat administration of Zilretta (triamcinolone acetonide extended-release; Flexion Therapeutics) appears to be safe and well-tolerated in patie... […]
via Google News and Bing News